Immunopharmacological studies of a disease-modifying antirheumatic drug iguratimod (T-614) - Its effect on immunoglobulin production and lymphocyte proliferation

Japanese Pharmacology and Therapeutics

Volumn 35, Issue 6, 2007, Pages 561-569

  Yamamoto, Tetsuya ^a   Aikawa, Yukihiko ^a   Funaki, Junko ^a   Tanaka, Keiichi ^a   Muramoto, Kenzo ^b  

^a TOYAMA CHEMICAL CO LTD   (Japan)

^b EISAI CO LTD   (Japan)

Author keywords

B cells; DMARD (disease modifying antirheumatic drug); Iguratimod (T 614); Immunoglobulin production; Lymphocyte proliferation

Indexed keywords

AURANOFIN; IGURATIMOD; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE; TERIFLUNOMIDE;

ANIMAL CELL; ANTIBODY PRODUCTION; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IC 50; IMMUNOPHARMACOLOGY; LYMPHOCYTE; NONHUMAN;

EID: 34547662917     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis : 2002 update. Arthritis Rheum 2002 ; 46 : 328-46.
2. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000 ; 343 : 1594-602.
3. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis : double-blind randomised controlled trial. Lancet 2004 ; 363 : 675-81.
4. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004 ; 350 : 2572-81.
5. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003 ; 349 : 1907-15.
6. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, et al. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis : a controlled, multicenter, double-blind, parallel-group study. Modern Rheumatology 2007 ; 17 : 1-9.
7. Tanaka K, Shimotori T, Makino S, Aikawa Y, Inaba T, Yoshida C, et al. Pharmacological studies of the new antiinflammatory agent 3-formylamino-7- methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one, 1st commun., antiinflammatory, analgesic and other related properties. Arzneimittelforschung 1992 ; 42 : 935-44.
8. Tanaka K, Shimotori T, Taniguchi Y, Eguchi M, Abe C. Pharmacological studies on T-614, a novel antiinflammatory agent : Effect on type II collagen-induced arthritis in DBA/1J mice and spontaneous arthritis in MRL/1 mice. Int J Immunother 1993 ; 9 : 69-78.
9. Aikawa Y, Tanuma N, Shin T, Makino S, Tanaka K, Matsumoto Y. A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis. J Neuroimmunol 1998 ; 89 : 35-42.
10. Tanaka K, Aikawa Y, Kawasaki H, Asaoka K, Inaba T, Yoshida C. Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 4th communication : inhibitory effect on the production of interleukin-1 and interleukin-6. J Pharmacobiodyn 1992 ; 15 : 649-55.
11. Tanaka K, Urata N, Mikami M, Ogasawara M, Matsunaga T, Terashima N, et al. Effect of iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26-induced cachexia in mice. Inflamm Res 2007 ; 56 : 17-23.
12. Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H, et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology (Oxford) 2003 ; 42 : 1365-71.
13. Coffman RL, Ohara J, Bond MW, Carty J, Zlotnik A, Paul WE. B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. J Immunol 1986 ; 136 : 4538-41.
14. Mond JJ, Brunswick M. In vitro assays for mouse B and T cells function. Isolation of B cells by percoll gradient centrifugation. In : Coligan JE, et al., editors. Current protocols in immunology. New York : John Wiley & Sons ; 1991. p. 3.8.11-16.
15. Japanese source
16. Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu YZ, Caulfield JP, et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995 ; 275 : 1043-9.
17. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990 ; 322 : 1277-89.
18. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials : the committee on outcome measures in rheumatoid arthritis clinical trials. Arthritis Rheum 1993 ; 36 : 729-40.
19. Japanese source
20. Matsumoto I, Staub A, Benoist C, Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 1999 ; 286 : 1732-5.
21. Benoist C, Mathis D. A revival of the B cell paradigm for rheumatoid arthritis pathogenesis? Arthritis Res 2000 ; 2 : 90-4.
22. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis : evidence for a pathogenetic role of B cells. Arthritis Rheum 2002 ; 46 : 2029-33.
23. Mosmann TR, Coffman RL. TH1 and TH2 cells : different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989 ; 7 : 145-73.
24. Comer S S, Jasin H E. In vitro immunomodulatory effects of sulfasalazine and its metabolites. J Rheumatol 1988 ; 15 : 580-6.
25. Japanese source
26. O'Meara AM, Brazil J, Reen DJ. The effect of methotrexate on in vitro immunoglobulin production. J Immunopharmacol 1985 ; 7 : 235-45.
27. Hirohata S, Lipsky PE. Comparative inhibitory effects of bucillamine and D-penicillamine on the function of human B cells and T cells. Arthritis Rheum 1994 ; 37 : 942-50.
28. Sheldon P, Webb C, Grindulis KA. Effect of sulphasalazine and its metabolites on mitogen induced transformation of lymphocytes-clues to its clinical action? Br J Rheumatol 1988 ; 27 : 344-9.
29. Johnston C, Russell AS, Aaron S. The effect of in vivo and in vitro methotrexate on lymphocyte proliferation as measured by the uptake of tritiated thymidine and tritiated guanosine. Clin Exp Rheumatol 1988 ; 6 : 391-3.
30. Sasano M, Nakata K. Inhibitory effects of bucillamine (SA96) on interferon-γ and interleukin 2 production in human peripheral blood mononuclear cells. Int J Immunother 1991 ; 7/2 : 87-94.